NeoGenomics, Inc. logo NEO - NeoGenomics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 1
BUY 22
HOLD 5
SELL 1
STRONG
SELL 0
| PRICE TARGET: $19.00 DETAILS
HIGH: $25.00
LOW: $13.00
MEDIAN: $19.00
CONSENSUS: $19.00
UPSIDE: 31.40%

Stock News

NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition

NeOnc Receives FDA Written Feedback on NEO212 CMC Development and Capsule-to-Tablet Transition

CALABASAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a clinical-stage life sciences company focused on the development of treatments for central nervous system cancers, today announced that it has received written feedback from the U.S. Food and Drug Administration (“FDA”) regarding the chemistry, manufacturing and controls (“CMC”) development program for NEO212, the Company's novel temozolomide-perillyl alcohol conjugate.

Jul 15, 2026 05:00 AM • globenewswire.com
NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone

NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone

Authorization covers all three NEO100 programs across adult Phase 1 through Phase 2, plus pediatric studies Extends NeOnc's UAE footprint beyond NEO212 and complements ongoing U.S. development, where NEO100 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations CALABASAS, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO100, the Company's lead candidate, an intranasally administered formulation of purified perillyl alcohol designed for non-invasive nose-to-brain delivery.

Jun 23, 2026 05:00 AM • globenewswire.com
NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development

NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development

Clearance enables Phase 2 evaluation of NEO212, the Company's oral perillyl alcohol-temozolomide conjugate, in the United Arab Emirates Follows completion of Phase 1 dose escalation and selection of 610 mg as the recommended Phase 2 dose Adds an international clinical pathway alongside continuing U.S. FDA discussions on a potential registrational pathway for NEO212 CALABASAS, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, today announced that the Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) status for NEO212, the Company's orally administered perillyl alcohol-temozolomide carbamate conjugate being developed for patients with aggressive brain tumors.

Jun 16, 2026 05:00 AM • globenewswire.com
NeoGenomics to Participate in Upcoming Investor Conferences

NeoGenomics to Participate in Upcoming Investor Conferences

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences: The 23rd Annual Craig-Hallum Institutional Investor Conference in Minneapolis Investor 1x1 meetings on Thursday, May 28th The Jefferies Global Healthcare Conference 2026 in New York Fireside chat on Thursday, June 4th, at 10:30am EDT, and investor 1x1 meetings A w.

May 15, 2026 05:05 AM • businesswire.com
NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts

NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts

CALABASAS, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing innovative therapies for central nervous system cancers, today announced that Chief Executive Officer, Executive Chairman, and President Amir Heshmatpour has significantly increased his personal ownership through consistent open-market purchases, including substantial buying in recent weeks, underscoring strong alignment with shareholders ahead of upcoming clinical and regulatory milestones.

May 05, 2026 05:00 AM • globenewswire.com

Price Targets